부산대학교 도서관

To link to full-text access for this article, visit this link: http://dx.doi.org/10.1097/01.ju.0000143192.68223.f7 Byline: RICARDO R. GONZALEZ, TIMOTHY FONG, NICOLE BELMAR, MARCIA SABAN, DIANE FELSEN, ALEXIS TE Keywords: bladder; cystitis, interstitial; tumor necrosis factor; anti-inflammatory agents; nerve growth factor Abstract: In interstitial cystitis (IC) inflammation induces and perpetuates neurotrophic changes in the bladder, resulting in the symptoms of frequency, urgency and pain. RDP58 (NH.sub.2-arg-norleucine (nle)-nle-arg-nle-nle-nle-gly-tyr-CONH.sub.2) (Sangstat Corp., Fremont, California) is a novel synthetic peptide that inhibits early signal transduction pathways for the expression of inflammatory cytokines. In this study we evaluated the effects of intravesical RDP58 on an established model of cystitis. Author Affiliation: From the Weill Medical College of Cornell University (RRG, DF, AT), New York, New York, Sangstat Medical Corp. (TF, NB), Fremont, California, and University of Oklahoma Health Sciences Center (MS), Oklahoma City, Oklahoma Article Note: (footnote) Submitted for publication April 15, 2004. Supported by The James Buchanan Brady Urological Foundation and SangStat Medical Co., Fremont, California. Study received Institutional Animal Care and Use Committee, Cornell University Weill Medical College approval, Fremont, California.